Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

BIRC3 (Baculoviral IAP repeat containing 3)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

BIRC3 mutation	Small Lymphocytic Lymphoma	BIRC3 mutation	Small Lymphocytic Lymphoma	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
BIRC3 mutation	Mantle Cell Lymphoma	BIRC3 mutation	Mantle Cell Lymphoma	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	FCR Resistant: C3 – Early Trials FCR Resistant : C3	FCR Resistant: C3 – Early Trials FCR Resistant : C3
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	BR Resistant: C3 – Early Trials BR Resistant : C3	BR Resistant: C3 – Early Trials BR Resistant : C3
BIRC3-MALT1 fusion	Marginal Zone Lymphoma	BIRC3-MALT1 fusion	Marginal Zone Lymphoma	R-CHOP Sensitive: C4 – Case Studies R-CHOP Sensitive : C4	R-CHOP Sensitive: C4 – Case Studies R-CHOP Sensitive : C4
BIRC3 deletion	Multiple Myeloma	BIRC3 deletion	Multiple Myeloma	bortezomib Sensitive: D – Preclinical bortezomib Sensitive : D	bortezomib Sensitive: D – Preclinical bortezomib Sensitive : D
BIRC3‐MALT1 fusion	Lymphoma	BIRC3‐MALT1 fusion	Lymphoma	MI-2 Sensitive: D – Preclinical MI-2 Sensitive : D	MI-2 Sensitive: D – Preclinical MI-2 Sensitive : D
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	DC-1-192 Sensitive: D – Preclinical DC-1-192 Sensitive : D	DC-1-192 Sensitive: D – Preclinical DC-1-192 Sensitive : D
BIRC2 overexpression + BIRC3 overexpression	Squamous Cell Carcinoma of Head and Neck	BIRC2 overexpression + BIRC3 overexpression	Squamous Cell Carcinoma of Head and Neck	AZD5582 Sensitive: D – Preclinical AZD5582 Sensitive : D	AZD5582 Sensitive: D – Preclinical AZD5582 Sensitive : D